01
Formulation
Pharmaceutical and nutraceutical formulations developed from the active outwards — stability, bioavailability and manufacturability treated as one problem rather than three.
ExploreWyteRock France
The science
behind the dse.
We formulate pharmaceutical and nutraceutical products, build the diagnostic instrumentation and buffer chemistry that measures them, and protect the thinking that makes both possible.
02
Diagnostics
Diagnostic instrumentation and the buffer systems it depends on. A result is only as trustworthy as the chemistry beneath it, so we take responsibility for both sides of the measurement.
Explore03
Innovation & IP
An active research programme and a deliberate approach to protecting what comes out of it. Filings are in progress; we discuss them when protection allows, and not before.
ExplorePosition
Three disciplines that belong together
Most organisations pick one: they formulate, or they measure, or they invent. Holding all three means a formulation is designed alongside the assay that will release it, and an instrument is designed knowing exactly what it will be asked to detect. Fewer handovers, fewer translation losses, and a shorter path from an idea to something that can actually be made.
Pillar 01
Pharmaceutical & nutraceutical formulation
A molecule that works in a flask is not yet a product. Formulation is the discipline that carries it the rest of the way — into a form that is stable on a shelf, absorbed by a body, and reproducible on a production line.
We work across the pharmaceutical and nutraceutical spectrum, and we treat the distinction between them as a regulatory one rather than a scientific one. The same rigour applies either way: characterise the active, understand what degrades it, design the matrix that protects it, and prove the result holds.
- Formulation development — solid, semi-solid and liquid oral forms, from first principles or from an existing brief.
- Excipient and matrix design — selecting the system that carries the active without fighting it.
- Stability and shelf-life — degradation pathways identified early, not discovered late.
- Bioavailability strategy — solubility and release profile treated as design targets.
- Scale-up readiness — formulations designed to survive the move from bench to batch.
- Analytical method development — because a formulation is only as good as the method that verifies it.
Pillar 02
Diagnostic machines & buffers
Diagnostics fail quietly. An instrument drifts, a buffer ages, a reagent loses a fraction of its activity — and the number on the screen still looks perfectly plausible. Guarding against that is the whole job.
We work on both halves of the measurement: the machine that reads the signal and the chemistry that produces it. Buffers are not a consumable afterthought in our view; they set the pH, ionic strength and stability window inside which an assay is either reliable or merely repeatable. Designing them alongside the instrument is how the two stay in agreement over a product's life.
- Diagnostic instrumentation — specification, development and evaluation of measurement hardware.
- Buffer and reagent systems — formulated for the assay they serve, not adapted to it.
- Assay support chemistry — stabilisers, diluents and controls developed as a matched set.
- Method validation — precision, linearity, robustness and the limits stated honestly.
- Instrument–reagent matching — the two designed together, so calibration holds.
- Lifecycle and stability — how the system behaves in month eighteen, not just on day one.
Pillar 03
Innovation & intellectual property
Patent pending
WyteRock maintains an active research programme, and an equally active discipline about what it says publicly. There are filings in progress. We will describe them when protection is in place, and not a day sooner.
That reticence is deliberate. Premature disclosure is one of the few mistakes in this field that cannot be undone — once a thing is public it is unpatentable, and the work that produced it becomes a gift to whoever moves fastest. Companies that treat their pipeline as marketing material tend to have less of a pipeline than they claim.
What we will say is how we operate: research directed at problems we have met directly in formulation and diagnostics, protection filed before conversation begins, and ownership held clearly enough that partners know exactly what they are dealing with.
- Applied research — directed at problems encountered in our own practice, not at speculation.
- Protection before disclosure — filings precede discussion, without exception.
- Clear ownership — contribution and entitlement recorded from the outset.
- Confidentiality as standard — technical dialogue proceeds under agreement.
- Portfolio stewardship — IP managed as an asset with a lifecycle, not a certificate in a drawer.
How we work
Quality is a method, not a claim
Evidence before assertion
Nothing is stated as established until data supports it. Where a question is open, we say it is open — which is the only way a client can plan around it.
Documented from the first run
Traceability is built in from the earliest development work rather than reconstructed later, because reconstruction is where records go wrong.
European base, global outlook
Headquartered in France and structured to work across borders, with the regulatory literacy that operating in Europe requires.
About
WyteRock France
WyteRock France is a science-led company working across pharmaceutical and nutraceutical formulation, diagnostic instrumentation and buffer chemistry, and the innovation that connects them.
The company is built around a straightforward conviction: the interesting problems in this industry sit in the gaps between specialisms. A formulation team that never speaks to an assay team will solve its own problem and create someone else's. We organised the business to close that gap rather than manage it.
We work with partners who need formulation capability, diagnostic development, or both — and who value a counterpart that will tell them what the data does not yet show. Our base in France places us within the European regulatory framework and within reach of the continent's research and manufacturing networks.
Bring us a difficult one.
Formulation that has stalled, a diagnostic that will not hold its calibration, or an idea that needs protecting before it needs discussing. Technical conversations proceed under confidentiality as a matter of course.
Contact
Start a conversation
Tell us what you are working on and who we would be speaking with. Enquiries of a technical nature are answered by someone technical.
For anything involving unpublished work, we are glad to put a confidentiality agreement in place before the detail begins.
General enquiries
Direct message